Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook – CNBC

The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.

#stockmarket #breaking

Leave a Reply

WP Twitter Auto Publish Powered By : XYZScripts.com